Global Cyproheptadine Market Insights, Forecast to 2028

Cyproheptadine is a serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
Market Analysis and Insights: Global Cyproheptadine Market
Due to the COVID-19 pandemic, the global Cyproheptadine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Patent accounting for % of the Cyproheptadine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Cyproheptadine market size is valued at US$ million in 2021, while the US and Europe Cyproheptadine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cyproheptadine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cyproheptadine include MSD, Aero-Chem, Allena Pharmaceuticals, Caillon and Hamonet, Teriak, Arena Pharmaceuticals, Pharma Arte, Fu Yuan Pharmaceutical and Panbiotic Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cyproheptadine Scope and Segment
Cyproheptadine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cyproheptadine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Patent
Generic
Segment by Application
Hospital
Drug Store
On-line
By Company
MSD
Aero-Chem
Allena Pharmaceuticals
Caillon and Hamonet
Teriak
Arena Pharmaceuticals
Pharma Arte
Fu Yuan Pharmaceutical
Panbiotic Laboratories
Royal Pharma
Novartis
General Pharma
Qualipharm
Faes Pharma
Apex Pharma
Cipla Medpro South Africa
Abbott
Kalbe
Laboratoires Servier
Medphano
Nichi-Iko Pharmaceutical
Teva
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE